
April 26 (Reuters) - Abbott Laboratories ABT.N:
NEW CLINICAL STUDY DATA SHOWCASE LONG-TERM, SUSTAINED BENEFITS OF ABBOTT'S VOLT™ PFA SYSTEM FOR PATIENTS WITH AFIB
ABBOTT LABORATORIES - VOLT PFA SYSTEM SHOWS STRONG 12-MONTH RESULTS
ABBOTT LABORATORIES - 83.5% PAF AND 58.1% PERSAF PATIENTS ARRHYTHMIA-FREE AFTER 12 MONTHS
ABBOTT LABORATORIES - ONLY 2.7% EXPERIENCED SAFETY ENDPOINT EVENT AFTER 12 MONTHS